You are viewing a limited version of this profile. To access i3's full capabilities.
Caribou Biosciences
Save
Company logo (jpg or png)
Parent company

Short description

Developer of CRISPR cellular engineering and analysis technology with applications in research, industrial biotech, agricultural, and therapeutics

Founded in 2011
Founded in

Company type Private Public ()
Company type

Industry Group materials & chemicals

Sector biotechnology

TRL Range 4-6
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Berkeley, CA Berkeley, United States
Address
City
State
Zip
Country

Parent Companies

Updated by Jonathan Koch at on 07/27/2017

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Date Company
Partnerships
Save
Date Partner Type
11/18/2014
Intellia Therapeutics Intellia Therapeutics
Newly formed company by Caribou and Atlas Venture to target therapies for genetic-based diseases.
View source    
Confirmed by Intellia Therapeutics
Licensee
Investment Rounds
Save

IPO INFORMATION

Date

IPO status

IPO Type

Amount

Initial shares

Ticker symbol

Exchange listed

Prospectus URL

Prospectus

Source URL

Source

Description

Date Investors Type Amount
03/04/2021 Farallon Capital Management Farallon Capital Management , PFM Health Sciences PFM Health Sciences , Ridgeback Capital Investments Ridgeback Capital Investments , AbbVie Ventures AbbVie Ventures , Adage Capital Partners Adage Capital Partners , Avego Bioscience Capital Avego Bioscience Capital , Avidity Partners Avidity Partners , Invus Invus , Janus Henderson Investors Janus Henderson Investors , LifeSci Venture Partners LifeSci Venture Partners , The Leukemia & Lymphoma Society Therapy Acceleration Program The Leukemia & Lymphoma Society Therapy Acceleration Program , Monashee Investment Management Monashee Investment Management , Point72 Ventures Point72 Ventures , Tekla Capital Management Tekla Capital Management , Heritage Medical Systems Heritage Medical Systems , Maverick Ventures Maverick Ventures , Aliment Capital Aliment Capital (17)
Post-money valuation of
The funds will be used to further develop Caribou's proprietary, next-generation CRISPR technology platform and to advance its pipeline of wholly-owned allogeneic immune cell therapies for oncology.
Growth Equity $115,000,000
Click to add IPO information
Products
Save
Product image Name Product status Revenue model Cost metrics

Cas9

Technology platform on genome editing

Product Development License of Usage
$/kW (current)
$/kW (projected)
$/kWh (current)
$/kWh (projected)
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font